Drugs / GX-12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00517569 | Aug 2006 → Dec 2009 | HIV infectious disease | Genexine, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GX-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00517569 ↗ |
| Modality | Other / unclassified | “GX-12 gene therapy” NCT00517569 ↗ |
| Route | Intramuscular | “i.m.” NCT00517569 ↗ |